Literature DB >> 26524266

Bendamustine-based conditioning for non-Hodgkin lymphoma autologous transplantation: an increasing risk of renal toxicity.

S Garciaz1, D Coso1, J-M Schiano de Collela1, F Broussais1, A-M Stoppa1, T Aurran1, C Chabannon1, A Helvig1, L Xerri1, D Blaise1, R Bouabdallah1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26524266     DOI： 10.1038/bmt.2015.257

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  15 in total

1.  Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

Authors:  Noel Milpied; Eric Deconinck; Fanny Gaillard; Vincent Delwail; Charles Foussard; Christian Berthou; Remy Gressin; Virginie Lucas; Philippe Colombat; Jean-Luc Harousseau
Journal:  N Engl J Med       Date:  2004-03-25       Impact factor: 91.245

2.  BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors.

Authors:  M D Caballero; V Rubio; J Rifon; I Heras; R García-Sanz; L Vázquez; B Vidriales; M C del Cañizo; M Corral; M Gonzalez; A León; E Jean-Paul; E Rocha; J M Moraleda; J F San Miguel
Journal:  Bone Marrow Transplant       Date:  1997-09       Impact factor: 5.483

3.  BeEAM (bendamustine, etoposide, cytarabine, melphalan) before autologous stem cell transplantation is safe and effective for resistant/relapsed lymphoma patients.

Authors:  Giuseppe Visani; Lara Malerba; Pietro Maria Stefani; Saveria Capria; Piero Galieni; Francesco Gaudio; Giorgina Specchia; Giovanna Meloni; Filippo Gherlinzoni; Claudio Giardini; Sadia Falcioni; Francesca Cuberli; Marco Gobbi; Barbara Sarina; Armando Santoro; Felicetto Ferrara; Marco Rocchi; Enrique M Ocio; Maria Dolores Caballero; Alessandro Isidori
Journal:  Blood       Date:  2011-08-03       Impact factor: 22.113

4.  High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma.

Authors:  A M Gianni; M Bregni; S Siena; C Brambilla; M Di Nicola; F Lombardi; L Gandola; C Tarella; A Pileri; F Ravagnani; P Valagussa; G Bonadonna
Journal:  N Engl J Med       Date:  1997-05-01       Impact factor: 91.245

5.  Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.

Authors:  H Hagberg; C Gisselbrecht
Journal:  Ann Oncol       Date:  2006-05       Impact factor: 32.976

6.  Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study.

Authors:  C Haioun; E Lepage; C Gisselbrecht; G Salles; B Coiffier; P Brice; A Bosly; P Morel; C Nouvel; H Tilly; P Lederlin; C Sebban; J Brière; P Gaulard; F Reyes
Journal:  J Clin Oncol       Date:  2000-08       Impact factor: 44.544

7.  A phase 1 study of bendamustine and melphalan conditioning for autologous stem cell transplantation in multiple myeloma.

Authors:  Tomer M Mark; Whitney Reid; Ruben Niesvizky; Usama Gergis; Roger Pearse; Sebastian Mayer; June Greenberg; Morton Coleman; Koen Van Besien; Tsiporah Shore
Journal:  Biol Blood Marrow Transplant       Date:  2013-02-20       Impact factor: 5.742

8.  High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

Authors:  T Philip; J O Armitage; G Spitzer; F Chauvin; S Jagannath; J Y Cahn; P Colombat; A H Goldstone; N C Gorin; M Flesh
Journal:  N Engl J Med       Date:  1987-06-11       Impact factor: 91.245

9.  A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.

Authors:  Marika Rasschaert; Dirk Schrijvers; Jan Van den Brande; Joke Dyck; Johan Bosmans; Karlheinz Merkle; Jan B Vermorken
Journal:  Anticancer Drugs       Date:  2007-06       Impact factor: 2.248

10.  BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.

Authors:  W Mills; R Chopra; A McMillan; R Pearce; D C Linch; A H Goldstone
Journal:  J Clin Oncol       Date:  1995-03       Impact factor: 44.544
View more
  5 in total

Review 1.  Carmustine replacement in intensive chemotherapy preceding reinjection of autologous HSCs in Hodgkin and non-Hodgkin lymphoma: a review.

Authors:  G Damaj; J Cornillon; K Bouabdallah; R Gressin; S Vigouroux; T Gastinne; F Ranchon; H Ghésquières; G Salles; I Yakoub-Agha; E Gyan
Journal:  Bone Marrow Transplant       Date:  2017-01-23       Impact factor: 5.483

2.  Safety and efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with relapsed/refractory lymphoma.

Authors:  Munira Shabbir-Moosajee; Samad Jehangir; Sobiya Sawani; Tariq Muhammed; Natasha Ali; Usman Sheikh; Salman Adil
Journal:  Blood Res       Date:  2019-06-25

3.  [Safety and the short-term efficacy of bendamustine in the conditioning regimen for autologous stem cell transplantation in patients with lymphoma].

Authors:  L C An; Y H Liu; J Y Wang; J J Ma; J Q Xu; K M Li; R X Wei; J R Sui; X Y Feng; X Q Liu; L M Chen; X X Chu
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2022-01-14

Review 4.  Autologous Stem Cell Transplantation in Hodgkin Lymphoma-Latest Advances in the Era of Novel Therapies.

Authors:  Yazeed Samara; Matthew Mei
Journal:  Cancers (Basel)       Date:  2022-03-29       Impact factor: 6.639

5.  BeEAM conditioning regimen is a safe, efficacious and economical alternative to BEAM chemotherapy.

Authors:  Logan Hahn; Hyun Lim; Tanner Dusyk; Waleed Sabry; Mohamed Elemary; Julie Stakiw; Pat Danyluk; Mark Bosch
Journal:  Sci Rep       Date:  2021-07-07       Impact factor: 4.379
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.